Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NNC9204-1706 in Overweight or Obese Males
NCT03095807Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2017
- Primary completion
- Aug 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NNC9204-1706 with Placebo (2 arms). Primary endpoint: Number of treatment-emergent adverse events. Started Mar 2017; status: completed.
02
Drugs
NNC9204-1706
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03095807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095807.